Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 202

1.

Therapeutic Drug Monitoring in Oncology: IATDMCT Recommendations for 5-Fluorouracil Therapy.

Beumer JH, Chu E, Allegra C, Tanigawara Y, Milano G, Diasio R, Won Kim T, Mathijssen RH, Zhang L, Arnold D, Muneoka K, Boku N, Joerger M.

Clin Pharmacol Ther. 2018 Jun 20. doi: 10.1002/cpt.1124. [Epub ahead of print] Review. No abstract available.

PMID:
29923599
2.

Effects of smoking and body mass index on the exposure of fentanyl in patients with cancer.

Kuip EJM, Oldenmenger WH, Thijs-Visser MF, de Bruijn P, Oosten AW, Oomen-de Hoop E, Koolen SLW, Van der Rijt CCD, Mathijssen RHJ.

PLoS One. 2018 Jun 8;13(6):e0198289. doi: 10.1371/journal.pone.0198289. eCollection 2018.

3.

Development of an ELISA to Measure Nivolumab and Pembrolizumab Serum Concentrations.

Basak EA, Wijkhuijs AJM, Mathijssen RHJ, Koolen SLW, Schreurs MWJ.

Ther Drug Monit. 2018 May 25. doi: 10.1097/FTD.0000000000000534. [Epub ahead of print]

PMID:
29847460
4.

Development and validation of an analytical method for regorafenib and its metabolites in mouse plasma.

Fu Q, Chen M, Hu S, McElroy CA, Mathijssen RH, Sparreboom A, Baker SD.

J Chromatogr B Analyt Technol Biomed Life Sci. 2018 Jul 15;1090:43-51. doi: 10.1016/j.jchromb.2018.05.005. Epub 2018 May 5.

PMID:
29783173
5.

Phase I Study of CC-486 Alone and in Combination With Carboplatin or nab‑paclitaxel in Patients With Relapsed or Refractory Solid Tumors.

Von Hoff DD, Rasco DW, Heath EI, Munster PN, Schellens JHM, Isambert N, Le Tourneau C, O'Neil BH, Mathijssen RH, Lopez-Martin JA, Edenfield WJ, Martín M, LoRusso PM, Bray GL, DiMartino J, Nguyen A, Liu K, Laille E, Bendell JC.

Clin Cancer Res. 2018 May 15. pii: clincanres.3716.2017. doi: 10.1158/1078-0432.CCR-17-3716. [Epub ahead of print]

PMID:
29764853
6.

Tamoxifen-induced fatty liver disease in a Caucasian patient.

Eechoute K, Mathijssen RHJ, van Gelder T.

Breast Cancer Res Treat. 2018 May 7. doi: 10.1007/s10549-018-4817-8. [Epub ahead of print] No abstract available.

PMID:
29736740
7.

Influence of aprepitant and localization of the patch on fentanyl exposure in patients with cancer using transdermal fentanyl.

Kuip EJM, Oldenmenger WH, Visser-Thijs MF, de Bruijn P, Oomen-de Hoop E, Mathijssen RHJ, Van der Rijt CCD, Koolen SW.

Oncotarget. 2018 Apr 6;9(26):18269-18276. doi: 10.18632/oncotarget.24812. eCollection 2018 Apr 6.

8.

Association between single-nucleotide polymorphisms and adverse events in nivolumab-treated non-small cell lung cancer patients.

Bins S, Basak EA, El Bouazzaoui S, Koolen SLW, Oomen-de Hoop E, van der Leest CH, van der Veldt AAM, Sleijfer S, Debets R, van Schaik RHN, Aerts JGJV, Mathijssen RHJ.

Br J Cancer. 2018 May;118(10):1296-1301. doi: 10.1038/s41416-018-0074-1. Epub 2018 Apr 26.

PMID:
29695768
9.

Predictors for doxorubicin-induced hematological toxicity and its association with outcome in advanced soft tissue sarcoma patients; a retrospective analysis of the EORTC-soft tissue and bone sarcoma group database.

Sleijfer S, Rizzo E, Litière S, Mathijssen RHJ, Judson IR, Gelderblom H, Van Der Graaf WTA, Gronchi A.

Acta Oncol. 2018 Mar 9:1-10. doi: 10.1080/0284186X.2018.1449248. [Epub ahead of print]

PMID:
29521151
10.

Individualization of Irinotecan Treatment: A Review of Pharmacokinetics, Pharmacodynamics, and Pharmacogenetics.

de Man FM, Goey AKL, van Schaik RHN, Mathijssen RHJ, Bins S.

Clin Pharmacokinet. 2018 Mar 8. doi: 10.1007/s40262-018-0644-7. [Epub ahead of print] Review.

PMID:
29520731
11.

A Genetic Polymorphism in CTLA-4 Is Associated with Overall Survival in Sunitinib-Treated Patients with Clear Cell Metastatic Renal Cell Carcinoma.

Liu X, Swen JJ, Diekstra MHM, Boven E, Castellano D, Gelderblom H, Mathijssen RHJ, Vermeulen SH, Oosterwijk E, Junker K, Roessler M, Alexiusdottir K, Sverrisdottir A, Radu MT, Ambert V, Eisen T, Warren A, Rodríguez-Antona C, García-Donas J, Böhringer S, Koudijs KKM, Kiemeney LALM, Rini BI, Guchelaar HJ.

Clin Cancer Res. 2018 May 15;24(10):2350-2356. doi: 10.1158/1078-0432.CCR-17-2815. Epub 2018 Feb 28.

PMID:
29490989
12.

An In-Depth Evaluation of the Validity and Logistics Surrounding the Testing of AR-V7 mRNA Expression in Circulating Tumor Cells.

Sieuwerts AM, Mostert B, van der Vlugt-Daane M, Kraan J, Beaufort CM, Van M, Prager WJC, De Laere B, Beije N, Hamberg P, Westgeest HM, Tascilar M, Dirix LY, Onstenk W, de Wit R, Lolkema MP, Mathijssen RHJ, Martens JWM, Sleijfer S.

J Mol Diagn. 2018 May;20(3):316-325. doi: 10.1016/j.jmoldx.2018.01.008. Epub 2018 Feb 21.

PMID:
29474983
13.

Genome-wide association study of paclitaxel and carboplatin disposition in women with epithelial ovarian cancer.

Gao B, Lu Y, Nieuweboer AJM, Xu H, Beesley J, Boere I, de Graan AM, de Bruijn P, Gurney H, J Kennedy C, Chiew YE, Johnatty SE, Beale P, Harrison M, Luccarini C, Conroy D, Mathijssen RHJ, R Harnett P, Balleine RL, Chenevix-Trench G, Macgregor S, de Fazio A.

Sci Rep. 2018 Jan 24;8(1):1508. doi: 10.1038/s41598-018-19590-w.

14.

OATP1B2 deficiency protects against paclitaxel-induced neurotoxicity.

Leblanc AF, Sprowl JA, Alberti P, Chiorazzi A, Arnold WD, Gibson AA, Hong KW, Pioso MS, Chen M, Huang KM, Chodisetty V, Costa O, Florea T, de Bruijn P, Mathijssen RH, Reinbolt RE, Lustberg MB, Sucheston-Campbell LE, Cavaletti G, Sparreboom A, Hu S.

J Clin Invest. 2018 Feb 1;128(2):816-825. doi: 10.1172/JCI96160. Epub 2018 Jan 16.

15.

Prognostic factors in men with metastatic castration-resistant prostate cancer treated with cabazitaxel.

Belderbos BPS, de Wit R, Hoop EO, Nieuweboer A, Hamberg P, van Alphen RJ, Bergman A, van der Meer N, Bins S, Mathijssen RHJ, van Soest RJ.

Oncotarget. 2017 Nov 16;8(63):106468-106474. doi: 10.18632/oncotarget.22474. eCollection 2017 Dec 5.

16.

Bioanalytical methods for the quantification of hydromorphone, fentanyl, norfentanyl, morphine, morphine-3ß-glucuronide and morphine-6ß-glucuronide in human plasma.

de Bruijn P, Kuip EJM, Lam MH, Mathijssen RHJ, Koolen SLW.

J Pharm Biomed Anal. 2018 Feb 5;149:475-481. doi: 10.1016/j.jpba.2017.11.035. Epub 2017 Nov 17.

PMID:
29182997
17.

Palliative chemotherapy and targeted therapies for esophageal and gastroesophageal junction cancer.

Janmaat VT, Steyerberg EW, van der Gaast A, Mathijssen RH, Bruno MJ, Peppelenbosch MP, Kuipers EJ, Spaander MC.

Cochrane Database Syst Rev. 2017 Nov 28;11:CD004063. doi: 10.1002/14651858.CD004063.pub4. Review.

PMID:
29182797
18.

Influence of Enzalutamide on Cabazitaxel Pharmacokinetics: a Drug-Drug Interaction Study in Metastatic Castration-resistant Prostate Cancer (mCRPC) Patients.

Belderbos BPS, Bins S, van Leeuwen RWF, Oomen-de Hoop E, van der Meer N, de Bruijn P, Hamberg P, Overkleeft ENM, van der Deure WM, Lolkema MP, de Wit R, Mathijssen RHJ.

Clin Cancer Res. 2018 Feb 1;24(3):541-546. doi: 10.1158/1078-0432.CCR-17-2336. Epub 2017 Nov 17.

PMID:
29150561
19.

Factors Affecting the Association of Proton Pump Inhibitors and Capecitabine Efficacy in Advanced Gastroesophageal Cancer.

Hussaarts KGAM, van Leeuwen RWF, Mathijssen RHJ.

JAMA Oncol. 2018 Feb 1;4(2):263-264. doi: 10.1001/jamaoncol.2016.7019. No abstract available.

PMID:
29098281
20.

Genetic polymorphisms in angiogenesis-related genes are associated with worse progression-free survival of patients with advanced gastrointestinal stromal tumours treated with imatinib.

Verboom MC, Kloth JSL, Swen JJ, van der Straaten T, Bovée JVMG, Sleijfer S, Reyners AKL, Mathijssen RHJ, Guchelaar HJ, Steeghs N, Gelderblom H.

Eur J Cancer. 2017 Nov;86:226-232. doi: 10.1016/j.ejca.2017.09.025. Epub 2017 Oct 18.

PMID:
29054076
21.

Pharmacokinetic Optimization of Everolimus Dosing in Oncology: A Randomized Crossover Trial.

Verheijen RB, Atrafi F, Schellens JHM, Beijnen JH, Huitema ADR, Mathijssen RHJ, Steeghs N.

Clin Pharmacokinet. 2018 May;57(5):637-644. doi: 10.1007/s40262-017-0582-9.

22.

Inhibition of OATP1B1 by tyrosine kinase inhibitors: in vitro-in vivo correlations.

Hu S, Mathijssen RHJ, de Bruijn P, Baker SD, Sparreboom A.

Br J Cancer. 2017 Aug 22;117(5):e3. doi: 10.1038/bjc.2017.217. Epub 2017 Jul 13.

23.

Understanding how coping strategies and quality of life maintain hope in patients deliberating phase I trial participation.

van der Biessen DA, van der Helm PG, Klein D, van der Burg S, Mathijssen RH, Lolkema MP, de Jonge MJ.

Psychooncology. 2018 Jan;27(1):163-170. doi: 10.1002/pon.4487. Epub 2017 Jul 26.

PMID:
28665008
24.

Sorafenib-Induced Changes in Thyroid Hormone Levels in Patients Treated for Hepatocellular Carcinoma.

Beukhof CM, van Doorn L, Visser TJ, Bins S, Visser WE, van Heerebeek R, van Kemenade FJ, de Rijke YB, de Herder WW, Chaker L, Mathijssen RH, Peeters RP.

J Clin Endocrinol Metab. 2017 Aug 1;102(8):2922-2929. doi: 10.1210/jc.2016-4025.

PMID:
28575418
25.

Evaluation of KDR rs34231037 as a predictor of sunitinib efficacy in patients with metastatic renal cell carcinoma.

Apellániz-Ruiz M, Diekstra MH, Roldán JM, Boven E, Castellano D, Gelderblom H, Mathijssen RHJ, Swen JJ, Böhringer S, García-Donás J, Rini BI, Guchelaar HJ, Rodríguez-Antona C.

Pharmacogenet Genomics. 2017 Jun;27(6):227-231. doi: 10.1097/FPC.0000000000000280.

PMID:
28430711
26.

Imatinib treatment of poor prognosis mesenchymal-type primary colon cancer: a proof-of-concept study in the preoperative window period (ImPACCT).

Ubink I, Bloemendal HJ, Elias SG, Brink MA, Schwartz MP, Holierhoek YCW, Verheijen PM, Boerman AW, Mathijssen RHJ, de Leng WWJ, de Weger RA, van Grevenstein WMU, Koopman M, Lolkema MP, Kranenburg O, Borel Rinkes IHM.

BMC Cancer. 2017 Apr 19;17(1):282. doi: 10.1186/s12885-017-3264-y.

27.

Towards better dose individualisation: metabolic phenotyping to predict cabazitaxel pharmacokinetics in men with prostate cancer.

Janssen A, Verkleij CPM, van der Vlist A, Mathijssen RHJ, Bloemendal HJ, Ter Heine R.

Br J Cancer. 2017 May 9;116(10):1312-1317. doi: 10.1038/bjc.2017.91. Epub 2017 Apr 11.

28.

Nivolumab for Squamous-Cell Cancer of Head and Neck.

Bins S, van Meerten E, Mathijssen RH.

N Engl J Med. 2017 Feb 9;376(6):595-6. No abstract available.

PMID:
28181785
29.

Genetic polymorphisms as predictive biomarker of survival in patients with gastrointestinal stromal tumors treated with sunitinib.

Kloth JSL, Verboom MC, Swen JJ, van der Straaten T, Sleijfer S, Reyners AKL, Steeghs N, Gelderblom H, Guchelaar HJ, Mathijssen RHJ.

Pharmacogenomics J. 2018 Jan;18(1):49-55. doi: 10.1038/tpj.2016.83. Epub 2017 Jan 24.

PMID:
28117434
30.

Tyrosine Kinase Inhibitors and Proton Pump Inhibitors: An Evaluation of Treatment Options.

van Leeuwen RWF, Jansman FGA, Hunfeld NG, Peric R, Reyners AKL, Imholz ALT, Brouwers JRBJ, Aerts JG, van Gelder T, Mathijssen RHJ.

Clin Pharmacokinet. 2017 Jul;56(7):683-688. doi: 10.1007/s40262-016-0503-3.

31.

Individualized Tamoxifen Dose Escalation-Letter.

Koolen SL, Bins S, Mathijssen RH.

Clin Cancer Res. 2016 Dec 15;22(24):6300. No abstract available.

32.

Meta-analysis on the association of VEGFR1 genetic variants with sunitinib outcome in metastatic renal cell carcinoma patients.

Liu X, Swen JJ, Boven E, Castellano D, Gelderblom H, Mathijssen RH, Rodríguez-Antona C, García-Donas J, Rini BI, Guchelaar HJ.

Oncotarget. 2017 Jan 3;8(1):1204-1212. doi: 10.18632/oncotarget.13597.

33.

A Prospective Population Pharmacokinetic Study on Morphine Metabolism in Cancer Patients.

Oosten AW, Abrantes JA, Jönsson S, Matic M, van Schaik RHN, de Bruijn P, van der Rijt CCD, Mathijssen RHJ.

Clin Pharmacokinet. 2017 Jul;56(7):733-746. doi: 10.1007/s40262-016-0471-7.

34.

A phase I pharmacokinetic and safety study of cabazitaxel in adult cancer patients with normal and impaired renal function.

Azaro A, Rodón J, Machiels JP, Rottey S, Damian S, Baird R, Garcia-Corbacho J, Mathijssen RH, Clot PF, Wack C, Shen L, de Jonge MJ.

Cancer Chemother Pharmacol. 2016 Dec;78(6):1185-1197. Epub 2016 Oct 27.

35.

A review of factors explaining variability in fentanyl pharmacokinetics; focus on implications for cancer patients.

Kuip EJ, Zandvliet ML, Koolen SL, Mathijssen RH, van der Rijt CC.

Br J Clin Pharmacol. 2017 Feb;83(2):294-313. doi: 10.1111/bcp.13129. Epub 2016 Oct 29. Review.

36.

Effects of Budesonide on Cabazitaxel Pharmacokinetics and Cabazitaxel-Induced Diarrhea: A Randomized, Open-Label Multicenter Phase II Study.

Nieuweboer AJ, de Graan AM, Hamberg P, Bins S, van Soest RJ, van Alphen RJ, Bergman AM, Beeker A, van Halteren H, Ten Tije AJ, Zuetenhorst H, van der Meer N, Chitu D, de Wit R, Mathijssen RH; Dutch Uro-Oncology Studygroup (DUOS).

Clin Cancer Res. 2017 Apr 1;23(7):1679-1683. doi: 10.1158/1078-0432.CCR-16-2110. Epub 2016 Oct 4.

37.

Implementation of a Multicenter Biobanking Collaboration for Next-Generation Sequencing-Based Biomarker Discovery Based on Fresh Frozen Pretreatment Tumor Tissue Biopsies.

Bins S, Cirkel GA, Gadellaa-Van Hooijdonk CG, Weeber F, Numan IJ, Bruggink AH, van Diest PJ, Willems SM, Veldhuis WB, van den Heuvel MM, de Knegt RJ, Koudijs MJ, van Werkhoven E, Mathijssen RH, Cuppen E, Sleijfer S, Schellens JH, Voest EE, Langenberg MH, de Jonge MJ, Steeghs N, Lolkema MP.

Oncologist. 2017 Jan;22(1):33-40. doi: 10.1634/theoncologist.2016-0085. Epub 2016 Sep 23.

38.

Reply to N. Singh et al.

van Leeuwen RWF, van Gelder T, Aerts JG, Mathijssen RHJ.

J Clin Oncol. 2016 Nov 20;34(33):4054. doi: 10.1200/JCO.2016.68.9356. Epub 2016 Oct 31. No abstract available.

PMID:
27551130
39.

Loss of SLCO1B3 drives taxane resistance in prostate cancer.

de Morrée ES, Böttcher R, van Soest RJ, Aghai A, de Ridder CM, Gibson AA, Mathijssen RH, Burger H, Wiemer EA, Sparreboom A, de Wit R, van Weerden WM.

Br J Cancer. 2016 Sep 6;115(6):674-81. doi: 10.1038/bjc.2016.251. Epub 2016 Aug 18.

40.

Development of a Pharmacokinetic Model to Describe the Complex Pharmacokinetics of Pazopanib in Cancer Patients.

Yu H, van Erp N, Bins S, Mathijssen RH, Schellens JH, Beijnen JH, Steeghs N, Huitema AD.

Clin Pharmacokinet. 2017 Mar;56(3):293-303. doi: 10.1007/s40262-016-0443-y.

PMID:
27534647
41.

Polymorphisms in SLCO1B1 and UGT1A1 are associated with sorafenib-induced toxicity.

Bins S, Lenting A, El Bouazzaoui S, van Doorn L, Oomen-de Hoop E, Eskens FA, van Schaik RH, Mathijssen RH.

Pharmacogenomics. 2016 Sep;17(14):1483-90. doi: 10.2217/pgs-2016-0063. Epub 2016 Aug 17.

PMID:
27533851
42.

Opioid treatment failure in cancer patients: the role of clinical and genetic factors.

Oosten AW, Matic M, van Schaik RH, Look MP, Jongen JL, Mathijssen RH, van der Rijt CC.

Pharmacogenomics. 2016 Aug;17(13):1391-403. doi: 10.2217/pgs-2016-0082. Epub 2016 Jul 29. Erratum in: Pharmacogenomics. 2017 May;18(7):743-748.

PMID:
27472837
43.

Individualized Pazopanib Dosing: A Prospective Feasibility Study in Cancer Patients.

Verheijen RB, Bins S, Mathijssen RH, Lolkema MP, van Doorn L, Schellens JH, Beijnen JH, Langenberg MH, Huitema AD, Steeghs N; Dutch Pharmacology Oncology Group.

Clin Cancer Res. 2016 Dec 1;22(23):5738-5746. Epub 2016 Jul 28.

44.

Prospective Analysis in GIST Patients on the Role of Alpha-1 Acid Glycoprotein in Imatinib Exposure.

Bins S, Eechoute K, Kloth JS, de Man FM, Oosten AW, de Bruijn P, Sleijfer S, Mathijssen RH.

Clin Pharmacokinet. 2017 Mar;56(3):305-310. doi: 10.1007/s40262-016-0441-0.

45.

Influence of the Acidic Beverage Cola on the Absorption of Erlotinib in Patients With Non-Small-Cell Lung Cancer.

van Leeuwen RW, Peric R, Hussaarts KG, Kienhuis E, IJzerman NS, de Bruijn P, van der Leest C, Codrington H, Kloover JS, van der Holt B, Aerts JG, van Gelder T, Mathijssen RH.

J Clin Oncol. 2016 Apr 20;34(12):1309-14. doi: 10.1200/JCO.2015.65.2560. Epub 2016 Feb 8. Erratum in: J Clin Oncol. 2016 Aug 10;34(23):2806.

PMID:
26858332
46.

Macrocytosis as a potential parameter associated with survival after tyrosine kinase inhibitor treatment.

Kloth JSL, Hamberg P, Mendelaar PAJ, Dulfer RR, van der Holt B, Eechoute K, Wiemer EAC, Kruit WHJ, Sleijfer S, Mathijssen RHJ.

Eur J Cancer. 2016 Mar;56:101-106. doi: 10.1016/j.ejca.2015.12.019. Epub 2016 Feb 1.

PMID:
26841094
47.

Sunitinib-induced hypertension in CYP3A4 rs4646437 A-allele carriers with metastatic renal cell carcinoma.

Diekstra MH, Belaustegui A, Swen JJ, Boven E, Castellano D, Gelderblom H, Mathijssen RH, García-Donas J, Rodríguez-Antona C, Rini BI, Guchelaar HJ.

Pharmacogenomics J. 2017 Jan;17(1):42-46. doi: 10.1038/tpj.2015.100. Epub 2016 Jan 26.

PMID:
26810136
48.

Treatment with subcutaneous and transdermal fentanyl: results from a population pharmacokinetic study in cancer patients.

Oosten AW, Abrantes JA, Jönsson S, de Bruijn P, Kuip EJ, Falcão A, van der Rijt CC, Mathijssen RH.

Eur J Clin Pharmacol. 2016 Apr;72(4):459-67. doi: 10.1007/s00228-015-2005-x. Epub 2016 Jan 14.

49.

Development and clinical validation of an LC-MS/MS method for the quantification of pazopanib in DBS.

Verheijen RB, Bins S, Thijssen B, Rosing H, Nan L, Schellens JH, Mathijssen RH, Lolkema MP, Beijnen JH, Steeghs N, Huitema AD.

Bioanalysis. 2016;8(2):123-34. doi: 10.4155/bio.15.235. Epub 2015 Dec 10.

PMID:
26652864
50.

miR-634 restores drug sensitivity in resistant ovarian cancer cells by targeting the Ras-MAPK pathway.

van Jaarsveld MT, van Kuijk PF, Boersma AW, Helleman J, van IJcken WF, Mathijssen RH, Pothof J, Berns EM, Verweij J, Wiemer EA.

Mol Cancer. 2015 Nov 17;14:196. doi: 10.1186/s12943-015-0464-4.

Supplemental Content

Loading ...
Support Center